sofidexFor patientsAre you a clinician? Clinical site

Health Library  ›  News  ›  Health notices · Sunday 4 October

Updates ·

Health notices · Sunday 4 October

3 notices from the agencies today, in plain words, each with the original linked.

About 1 minute to readNoticePublished October 2026

PDF
a plain paper envelope and an unopened cardboard box on a table

Frozen pizzas recalled for undeclared soy allergen on labels

Centers for Disease Control and Prevention (CDC) · Food safety

If you have a soy allergy, this CDC notice matters: some frozen pizzas may contain soy ingredients but the label did not declare them.

The recall covers Saint Francis Apizza LLC frozen pizzas sold in the following varieties: Pepperoni, Plain Cheese, Supreme, and Mushroom and Onion.

The affected products were sold in Cincinnati, Ohio and the notice was published October 1, 2026. Check whether your pizza matches the recalled items.

What to do

  • Follow the recall instructions for the recalled Saint Francis Apizza LLC frozen pizzas.

Read the original notice

FDA approves fosaprepitant (FOCINVEZ) for chemotherapy nausea prevention

FDA · Approval

If you or your child is 6 months or older and receiving highly or moderately emetogenic cancer chemotherapy, the FDA has approved FOCINVEZ to help prevent acute and delayed nausea and vomiting during initial and repeat courses, when used with other antiemetic medicines.

FOCINVEZ is a substance P/neurokinin-1 (NK1) receptor antagonist. That means it blocks specific body signals involved in nausea and vomiting, but it is not studied for treating nausea and vomiting that has already started.

This approval is for prevention (not treatment of established symptoms), so your care team will use it alongside other antiemetic agents as appropriate for your chemotherapy plan.

Read the original notice

FDA approval for liposomal doxorubicin hydrochloride injection

FDA · Approval

If you are being treated for certain cancers, the US Food and Drug Administration has approved DOXORUBICIN HYDROCHLORIDE injection, including use as part of multi-agent adjuvant chemotherapy after breast cancer surgery.

This medicine is an anthracycline topoisomerase inhibitor, which is a type of chemotherapy that interferes with cancer cell growth.

It may be indicated for treatment of acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, and multiple metastatic cancers listed in the label.

Read the original notice